Bristol Myers Squibb Company (NYSE:BMY) is Castleview Partners LLC's 3rd Largest Position

Castleview Partners LLC increased its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 23.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 67,896 shares of the biopharmaceutical company's stock after purchasing an additional 12,703 shares during the quarter. Bristol Myers Squibb makes up approximately 2.8% of Castleview Partners LLC's investment portfolio, making the stock its 3rd biggest position. Castleview Partners LLC's holdings in Bristol Myers Squibb were worth $4,141,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of BMY. Norges Bank bought a new position in Bristol Myers Squibb in the 4th quarter worth $1,989,525,000. Ameriprise Financial Inc. raised its holdings in Bristol Myers Squibb by 59.9% during the fourth quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock valued at $1,814,341,000 after acquiring an additional 12,011,983 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in Bristol Myers Squibb by 701.2% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,470,106 shares of the biopharmaceutical company's stock valued at $705,309,000 after acquiring an additional 10,913,708 shares during the period. Wellington Management Group LLP raised its holdings in Bristol Myers Squibb by 3,880.0% during the fourth quarter. Wellington Management Group LLP now owns 5,977,505 shares of the biopharmaceutical company's stock valued at $338,088,000 after acquiring an additional 5,827,317 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in Bristol Myers Squibb during the fourth quarter valued at about $257,618,000. 76.41% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP Samit Hirawat purchased 4,250 shares of the company's stock in a transaction that occurred on Friday, April 25th. The stock was bought at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the transaction, the executive vice president now owns 83,513 shares in the company, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 0.07% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

BMY has been the topic of a number of recent analyst reports. Jefferies Financial Group decreased their price target on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Argus raised Bristol Myers Squibb to a "hold" rating in a report on Friday, April 25th. UBS Group decreased their price target on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a report on Friday, April 11th. The Goldman Sachs Group reissued a "neutral" rating and set a $55.00 price target (down from $67.00) on shares of Bristol Myers Squibb in a report on Tuesday, April 8th. Finally, Wall Street Zen cut Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $58.00.

Bristol Myers Squibb Trading Up 0.1%

BMY traded up $0.03 on Friday, hitting $46.87. The company had a trading volume of 47,283,703 shares, compared to its average volume of 12,989,833. The company has a market cap of $95.38 billion, a PE ratio of 17.55, a PEG ratio of 1.39 and a beta of 0.38. Bristol Myers Squibb Company has a 12-month low of $39.35 and a 12-month high of $63.33. The company has a quick ratio of 1.17, a current ratio of 1.28 and a debt-to-equity ratio of 2.65. The business's fifty day simple moving average is $48.20 and its 200 day simple moving average is $54.32.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. The company had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The firm's revenue was down 5.6% on a year-over-year basis. During the same quarter last year, the business posted ($4.40) earnings per share. Equities research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be given a $0.62 dividend. The ex-dividend date is Thursday, July 3rd. This represents a $2.48 annualized dividend and a yield of 5.29%. Bristol Myers Squibb's dividend payout ratio is currently 92.88%.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.